In the 1920s, Bayer—then called Schering AG—made a significant contribution to understanding the molecular structure of sex hormones and launched the world's first oestrogen preparation for menopause management. This firmly set Bayer as a pioneer in women’s healthcare and, in 1961, Bayer became the first company to launch a contraceptive pill in Europe, the combined oral contraceptive Anovlar® (norethisterone acetate/ethinylestradiol)1. Anovlar is no longer produced.
More recent innovations include the introduction of Kyleena® (19.5mg intrauterine delivery system levonorgestrel) a low-dose, levonorgestrel-releasing intrauterine delivery system which was launched in the UK in 2018.2
First European birth control pill, the combined oral contraceptive Anovlar® (norethisterone/ethinylestradiol). Anovlar is no longer produced.
Progestogen-only pill (mini-pill)
Progestogen-only emergency contraception, launched in the UK
Low-estrogen dose contraceptive pill
First pill to treat premenstrual dysphoric disorder, a severe form of premenstrual syndrome, in the US for women who choose the contraceptive pill for birth control
PP-PF-WHC-GB-1006 May 2022
Reporting adverse events and quality complaints
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 01182063500 or email: email@example.com
Further information is available on the “contact” tab at www.bayer.co.uk.